SciSure is revolutionizing laboratories across the globe with innovative digital solutions designed for the future. Our Digital Lab Platform (DLP) integrates essential tools such as Electronic Lab Notebooks (ELN) and Laboratory Information Management Systems (LIMS), alongside cutting-edge technologies like artificial intelligence and machine learning. Engineered for effortless integration with your laboratory's existing hardware and software, this platform significantly boosts flexibility, security, and overall efficiency. By streamlining and optimizing your research and development processes within a secure and compliant framework, we enable researchers to focus more on driving innovation. Our dedicated team of experts is here to assist you throughout every phase of your digital lab transformation journey, ensuring a smooth transition.
Learn more
RunPod offers a robust cloud infrastructure designed for effortless deployment and scalability of AI workloads utilizing GPU-powered pods. By providing a diverse selection of NVIDIA GPUs, including options like the A100 and H100, RunPod ensures that machine learning models can be trained and deployed with high performance and minimal latency. The platform prioritizes user-friendliness, enabling users to create pods within seconds and adjust their scale dynamically to align with demand. Additionally, features such as autoscaling, real-time analytics, and serverless scaling contribute to making RunPod an excellent choice for startups, academic institutions, and large enterprises that require a flexible, powerful, and cost-effective environment for AI development and inference. Furthermore, this adaptability allows users to focus on innovation rather than infrastructure management.
Learn more
NVIDIA Parabricks
NVIDIA® Parabricks® is distinguished as the only comprehensive suite of genomic analysis tools that utilizes GPU acceleration to deliver swift and accurate genome and exome assessments for a variety of users, including sequencing facilities, clinical researchers, genomics scientists, and developers of high-throughput sequencing technologies. This cutting-edge platform incorporates GPU-optimized iterations of popular tools employed by computational biologists and bioinformaticians, resulting in significantly enhanced runtimes, improved scalability of workflows, and lower computing costs. Covering the full spectrum from FastQ files to Variant Call Format (VCF), NVIDIA Parabricks markedly elevates performance across a range of hardware configurations equipped with NVIDIA A100 Tensor Core GPUs. Genomics researchers can experience accelerated processing throughout their complete analysis workflows, encompassing critical steps like alignment, sorting, and variant calling. When users deploy additional GPUs, they can achieve near-linear scaling in computational speed relative to conventional CPU-only systems, with some reporting acceleration rates as high as 107X. This exceptional level of efficiency establishes NVIDIA Parabricks as a vital resource for all professionals engaged in genomic analysis, making it indispensable for advancing research and clinical applications alike. As genomic studies continue to evolve, the capabilities of NVIDIA Parabricks position it at the forefront of innovation in this rapidly advancing field.
Learn more
Genomenon
Pharmaceutical firms need a wealth of genomic information to successfully execute precision medicine strategies; however, they often utilize only a fraction—around 10%—of the total data at their disposal for decision-making. Genomenon offers an extensive database to counter this limitation. Their Prodigy™ Patient Landscapes deliver a cost-effective and efficient approach for conducting natural history research, which is crucial for developing treatments for rare conditions by expanding the understanding of both past and future health data. Employing a sophisticated AI-driven process, Genomenon meticulously analyzes each patient referenced in the medical literature much faster than traditional methods. It is essential to capture all pertinent insights by examining every genomic biomarker highlighted in scholarly articles. Each scientific assertion is backed by solid evidence sourced from medical literature, enabling researchers to identify all genetic factors and pinpoint variants classified as pathogenic according to ACMG clinical criteria, thus streamlining the creation of targeted therapies. By adopting this thorough strategy, pharmaceutical companies can significantly boost their research efficiency and, in turn, enhance patient outcomes. This innovative model not only fosters advancements in drug development but also contributes to a deeper understanding of genetic influences on health.
Learn more